Polycystic ovary syndrome and early-onset preeclampsia: Reproductive manifestations of increased cardiovascular risk

Menopause

Volumn 17, Issue 5, 2010, Pages 990-996

  Veltman Verhulst, Susanne M ^a   Van Rijn, Bas B ^a,b   Westerveld, H Egbertine ^a   Franx, Arie ^c   Bruinse, Hein W ^a   Fauser, Bart C J M ^a   Goverde, Angelique J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c CPRLab   (Netherlands)

Author keywords

Cardiovascular disease; Polycystic ovary syndrome; Preeclampsia; Prevention; Women

Indexed keywords

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; FEMALE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; OVARY POLYCYSTIC DISEASE; PREECLAMPSIA; SMOKING HABIT;

ADULT; BODY MASS INDEX; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INCIDENCE; METABOLIC SYNDROME X; OBESITY; POLYCYSTIC OVARY SYNDROME; PRE-ECLAMPSIA; PREGNANCY; RISK FACTORS;

EID: 77957722355     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181ddf705     Document Type: Article

References (41)

1. World Health Organization. WHO Statistical Information System. Available at: http://www.who.int/whosis/mort/download/en/. Accessed September 29, 2009.
2. Centers for Disease Control and Prevention. About compressed mortality, 1999-2000. Available at: http://wonder.cdc.gov/cmf-icd10.html. Accessed October 7, 2009.
3. CBS. Centraal Bureau voor de Statistiek. Available at: http://www.cbs.nl/nl-NL/menu/themas/gezondheid-welzijn/cijfers/default.htm. Accessed September 9, 2009.
4. Wenger NK. Preventing cardiovascular disease in women: an update. Clin Cardiol 2008;31:109-113.
5. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Diabetes Care 2008;31: 1686-1696.
6. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol 2007;49:1230-1250. (Pubitemid 46400344)
7. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001;104:2158-2163.
8. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106:388-391.
9. Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 1998;97:1876-1887.
10. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 2007;297:611-619.
11. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.
12. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007;335:974.
13. Glueck CJ, Morrison JA, Goldenberg N, Wang P. Coronary heart disease risk factors in adult premenopausal white women with polycystic ovary syndrome compared with a healthy female population. Metabolism 2009;58:714-721.
14. Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ 2002;325: 157-160.
15. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010;25: 544-551.
16. Morris RK, Cnossen JS, Langejans M, et al. Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis. BMC Pregnancy Childbirth 2008;8:33.
17. Essah PA, Wickham EP, Nestler JE. The metabolic syndrome in poly-cystic ovary syndrome. Clin Obstet Gynecol 2007;50:205-225.
18. Forest JC, Girouard J, Masse J, et al. Early occurrence of metabolic syndrome after hypertension in pregnancy. Obstet Gynecol 2005;105: 1373-1380.
19. Girouard J, Giguere Y, Moutquin JM, Forest JC. Previous hypertensive disease of pregnancy is associated with alterations of markers of insulin resistance. Hypertension 2007;49:1056-1062.
20. Goverde AJ, van Koert AJ, Eijkemans MJ, et al. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod 2009;24:710-717.
21. Manten GT, Sikkema MJ, Voorbij HA, Visser GH, Bruinse HW, Franx A. Risk factors for cardiovascular disease in women with a history of pregnancy complicated by preeclampsia or intrauterine growth restriction. Hypertens Pregnancy 2007;26:39-50.
22. Orio F Jr, Palomba S, Spinelli L, et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 2004;89:3696-3701.
23. Westerveld HE, Hoogendoorn M, de Jong AW, Goverde AJ, Fauser BC, Dallinga-Thie GM. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights. Pharmacol Ther 2008; 119:223-241.
24. Harskamp RE, Zeeman GG. Preeclampsia: at risk for remote cardiovascular disease. Am J Med Sci 2007;334:291-295.
25. Talbott EO, Zborowski JV, Sutton-Tyrrell K, McHugh-Pemu KP, Guzick DS. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001;28:111-133, vii.
26. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006; 12:673-683.
27. van Rijn BB, Hoeks LB, Bots ML, Franx A, Bruinse HW. Outcomes of subsequent pregnancy after first pregnancy with early-onset pre-eclampsia. Am J Obstet Gynecol 2006;195:723-728.
28. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20: IX-XIV.
29. Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 2004;103:981-991.
30. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47.
31. Sikkema JM, Franx A, Bruinse HW, van der Wijk NG, de Valk HW, Nikkels PG. Placental pathology in early onset pre-eclampsia and intra-uterine growth restriction in women with and without thrombophilia. Placenta 2002;23:337-342.
32. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004;59:141-154.
33. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
34. Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among U.S. adults. Obes Res 2003;11:1223-1231.
35. Ryan MC, Fenster Farin HM, Abbasi F, Reaven GM. Comparison of waist circumference versus body mass index in diagnosing metabolic syndrome and identifying apparently healthy subjects at increased risk of cardiovascular disease. Am J Cardiol 2008;102:40-46.
36. van der Heijden GJ, Donders AR, Stijnen T, Moons KG. Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example. J Clin Epidemiol 2006;59:1102-1109.
37. Oren A, Vos LE, Uiterwaal CS, et al. The Atherosclerosis Risk in Young Adults (ARYA) Study: rationale and design. Eur J Epidemiol 2003;18:715-727.
38. Viet AL, Hof van den S, Elvers LH, et al. Risicofactoren en gezondheids evaluatie Nederlandse bevolking, een Onderzoek op GGD'en (Regenboog project). Available at: http://www.rivm.nl/bibliotheek/rapporten/260854004.html. Accessed January 4, 2010.
39. Ferreira I, Twisk JW, van Mechelen W, Kemper HC, Stehouwer CD. Development of fatness, fitness, and lifestyle from adolescence to the age of 36 years: determinants of the metabolic syndrome in young adults: the Amsterdam Growth and Health Longitudinal Study. Arch Intern Med 2005;165:42-48.
40. Ramadhani MK, Grobbee DE, Bots ML, et al. Lower birth weight predicts metabolic syndrome in young adults: the Atherosclerosis Risk in Young Adults (ARYA)-Study. Atherosclerosis 2006;184:21-27.
41. Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:48-53.